The agent for Bobby Portis is calling the Milwaukee Bucks forward's use of Tramadol, the drug that has led to his suspension, ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid ...

Milwaukee Bucks forward Bobby Portis Jr. was suspended for 25 games without pay by the NBA on Thursday for violating the ...

the acting director of the FDA's Center for Drug Evaluation and Research, said in a statement. “A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate ...

Nitazenes were first synthesised in the 1950s by the Swiss pharmaceutical company, Ciba Aktiengesellschaft, as pain-relieving ...

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

New govt regulations and policies are pushing pharmaceutical sector in the right direction, says Highnoon Labs chairman.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The increasing availability of these and other synthetic drugs led the UK’s National Crime Agency (NCA) to warn in August ...

More than trade and tariff matters, it would be interesting to know where New Delhi stands with regards to the White House and Trump’s agenda on illegal immigrants.

The new product will launch at a list price of $15.50 per ... acting director of the FDA's Center for Drug Evaluation and Research (CDER). "A new non-opioid analgesic therapeutic class for acute ...